2024 IPO

Kyverna Therapeutics Stock

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

Sign up today and learn more about Kyverna Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Kyverna Therapeutics Stock

KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.

Funding History

January 2020$25.0M
January 2022$85.0M
August 2023$60.0M


Senior Vice President, Head of Research

Tom Van Blarcom

Board Observer

Heba Nowyhed

Board Observer

Desmond Padhi

Board Observer

Chris Liu

Board Member

Dominic Borie

Co-Founder and Chief Scientific Officer

Jeffrey Greve

Board Member

Mark Genovese

Board Member

Brian L. Kotzin

Chief Technical Officer

Karen Walker

Board Member

Daniel Spiegelman

Chairman of the Board

Ian Clark

Board Member

Fred Cohen

Board Member

Beth Seidenberg

Chief Executive Officer

Peter Maag


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: